{
    "id": 169,
    "name": "neuroendocrine tumor",
    "source": "DOID",
    "definition": "An endocrine gland cancer that has_material_basis_in neuroendocrine cells. [url:http\\://en.wikipedia.org/wiki/Neuroendocrine_cell, url:http\\://en.wikipedia.org/wiki/Neuroendocrine_tumor, url:http\\://www.cancer.gov/dictionary?CdrID=44904]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:169",
    "evidence": [
        {
            "id": 1152,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Sirolimus (rapamycin) slowed pituitary tumors and decreased the occurrence of thyroid tumors in Rb1+/- mice (PMID: 23454836).",
            "molecularProfile": {
                "id": 2007,
                "profileName": "RB1 loss"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 903,
                    "pubMedId": 23454836,
                    "title": "Rapamycin extends life span of Rb1+/- mice by inhibiting neuroendocrine tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23454836"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2270,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, an orthotopic mouse model treated with ZK 304709 demonstrated an 80% tumor growth reduction in neuroendocrine tumor cells with CDKN2A loss (PMID: 18829975).",
            "molecularProfile": {
                "id": 1806,
                "profileName": "CDKN2A loss"
            },
            "therapy": {
                "id": 2735,
                "therapyName": "ZK 304709",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2949,
                    "pubMedId": 18829975,
                    "title": "The oral multitarget tumour growth inhibitor, ZK 304709, inhibits growth of pancreatic neuroendocrine tumours in an orthotopic mouse model.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/18829975"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18074,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib/II trial, Surufatinib (HMPL-012) treatment resulted in an objective response rate of 19% (8/42) and 15% (6/39), a disease control rate of 91% (38/42) and 92% (36/39), and a median progression-free survival of 21.2 and 13.4 months in patients with advanced, well-differentiated pancreatic and extrapancreatic neuroendocrine tumors, respectively (PMID: 30833272; NCT02267967).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3666,
                "therapyName": "Surufatinib",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 15985,
                    "pubMedId": 30833272,
                    "title": "Surufatinib in Advanced Well-Differentiated Neuroendocrine Tumors: A Multicenter, Single-Arm, Open-Label, Phase Ib/II Trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30833272"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4876,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, Surufatinib (HMPL-012) demonstrated an objective response rate in 44% (8/18) of patients with neuroendocrine tumors (AACR; Mol Cancer Ther 2015;14(12 Suppl 2):Abstract nr A1).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3666,
                "therapyName": "Surufatinib",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4764,
                    "pubMedId": null,
                    "title": "First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors",
                    "url": "http://mct.aacrjournals.org/content/14/12_Supplement_2/A1.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4915,
            "approvalStatus": "FDA approved",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial (RADIANT-4) supporting FDA approval, Afinitor (everolimus) treatment significantly improved median progression-free survival (11.0 months) comparing to placebo (3.9 months) in patients with progressive neuroendocrine tumours of the lung or gastrointestinal tract origin (PMID: 26703889; NCT01524783).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 4800,
                    "pubMedId": 26703889,
                    "title": "Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26703889"
                },
                {
                    "id": 15547,
                    "pubMedId": null,
                    "title": "Afinitor (everolimus) FDA Drug Label",
                    "url": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=022334"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 5602,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, patients with neuroendocrine tumors treated with the combination of Cixutumumab, Sandostatin Lar Depot (octreotide acetate), and Afinitor (everolimus) demonstrated some efficacy, however, the drug combination did result in multiple non-dose limiting toxicities preventing long term tolerance (PMID: 25900182).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 3906,
                "therapyName": "Cixutumumab + Everolimus + Octreotide acetate",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5121,
                    "pubMedId": 25900182,
                    "title": "Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25900182"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 6680,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Mekinist (trametinib) and Tafinlar (dabrafenib) combination treatment resulted in a rapid and sustained clinical response in a patient with a rectal neuroendocrine tumor harboring a BRAF V600E mutation (PMID: 27048246).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 1066,
                "therapyName": "Dabrafenib + Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5733,
                    "pubMedId": 27048246,
                    "title": "BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27048246"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6681,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Mekinist (trametinib) and Zelboraf (vemurafenib) combination treatment resulted in a rapid and sustained clinical response in a patient with a rectal neuroendocrine tumor harboring a BRAF V600E mutation (PMID: 27048246).",
            "molecularProfile": {
                "id": 1,
                "profileName": "BRAF V600E"
            },
            "therapy": {
                "id": 4234,
                "therapyName": "Trametinib + Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 5733,
                    "pubMedId": 27048246,
                    "title": "BRAFV600E Mutations in High-Grade Colorectal Neuroendocrine Tumors May Predict Responsiveness to BRAF-MEK Combination Therapy.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27048246"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 7545,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II clinical trial, treatment with Inlyta (axitinib) resulted in a median overall progression-free survival (PFS) of 26.7 months, a 12-month PFS rate of 74.5%, and median overall survival of 45.3 months, and led to partial response in 3% (1/30) and stable disease in 70% (21/30) of patients with neuroendocrine tumors, with some tumor shrinkage in 68% (15/22) of patients (PMID: 27080472).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 649,
                "therapyName": "Axitinib",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 6415,
                    "pubMedId": 27080472,
                    "title": "A phase II study of axitinib in advanced neuroendocrine tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/27080472"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 9988,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, DS-3032b demonstrated safety and some preliminary activity in patients with advanced solid tumors, and resulted in prolonged stable disease in 2 patients with MDM2-amplification, 1 with liposarcoma and 1 with carcinoid tumor ((J Clin Oncol 34, 2016 (suppl; abstr 2581)).",
            "molecularProfile": {
                "id": 1425,
                "profileName": "MDM2 amp"
            },
            "therapy": {
                "id": 2079,
                "therapyName": "DS-3032b",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7837,
                    "pubMedId": null,
                    "title": "A phase 1 study of the MDM2 inhibitor DS-3032b in patients (pts) with advanced solid tumors and lymphomas.",
                    "url": "http://meetinglibrary.asco.org/content/166204-176"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11226,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial, addition of Pasireotide to Afinitor (everolimus) did not significantly affect progression free survival (16.8 vs 16.6 months) or overall disease control rate (77.2% vs 82.7%) in patients with well-differentiated, progressive pancreatic neuroendocrine tumors (PMID: 28327907).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 2261,
                "therapyName": "Everolimus + Pasireotide",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 9175,
                    "pubMedId": 28327907,
                    "title": "A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28327907"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 11336,
            "approvalStatus": "Phase III",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase III trial, addition of Afinitor (everolimus) to Octreotide did not significantly improve median overall survival (29.2 vs 35.2 months) compared to placebo in patients with advanced neuroendocrine tumors associated with carcinoid syndrome (PMID: 28444114).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5944,
                "therapyName": "Everolimus + Octreotide",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 9242,
                    "pubMedId": 28444114,
                    "title": "Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28444114"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 13894,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, combination of Vorolanib (X-82) and Afinitor (everolimus) resulted in stable disease ranging from 3-23 months in 10 patients with neuroendocrine tumors (Journal of Clinical Oncology 34, no. 15_suppl (May 20 2016) 2588-2588).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1272,
                "therapyName": "Everolimus + Vorolanib",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 11342,
                    "pubMedId": null,
                    "title": "Phase I study of X-82, an oral dual anti-VEGFR/PDGFR tyrosine kinase inhibitor, with everolimus in solid tumors.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2016.34.15_suppl.2588"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 16243,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial (KEYNOTE-028), Keytruda (pembrolizumab) treatment demonstrated safety and preliminary efficacy, resulted in objective response in 12% (3/25) of heavily pretreated patients with carcinoid tumors (lung, n=9; gut, n=7; other, n=9) and in 6% (1/16) of patients with pancreatic neuroendocrine tumors that had CD274 (PD-L1) expression in 1% or more of tumor cells by IHC, with stable disease in 60% (15/25) and 88% (14/16) of the patients respectively (Ann Oncol, 28(Suppl_5); NCT02054806).",
            "molecularProfile": {
                "id": 4746,
                "profileName": "CD274 positive"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 14387,
                    "pubMedId": null,
                    "title": "Pembrolizumab for patients with PD-L1-positive advanced carcinoid or pancreatic neuroendocrine tumors: Results from the KEYNOTE-028 study",
                    "url": "https://academic.oup.com/annonc/article/28/suppl_5/mdx368/4108699"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16262,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (KEYNOTE-158), Keytruda (pembrolizumab) treatment resulted in partial response in 3.7% (4/107, 3 pancreatic, 1 GI) and stable disease in 57.0% (61/107) of patients with heavily pretreated neuroendocrine tumors, all 4 responders were CD274 (PD-L1)-negative (Journal of Clinical Oncology 37, no. 4_suppl (February 1 2019) 190-190; NCT02628067).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 14402,
                    "pubMedId": null,
                    "title": "Pembrolizumab treatment of advanced neuroendocrine tumors: Results from the phase II KEYNOTE-158 study.",
                    "url": "http://ascopubs.org/doi/abs/10.1200/JCO.2019.37.4_suppl.190"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 17699,
            "approvalStatus": "Guideline",
            "evidenceType": "Actionable",
            "efficacyEvidence": "Keytruda (pembrolizumab) is included in guidelines as an option for patients with relapsed neuroendocrine tumors with high microsatellite instability, MSI-H, and no alternative options (NCCN.org).",
            "molecularProfile": {
                "id": 29714,
                "profileName": "MSI high"
            },
            "therapy": {
                "id": 1447,
                "therapyName": "Pembrolizumab",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 10889,
                    "pubMedId": null,
                    "title": "NCCN.org",
                    "url": "https://www.nccn.org/professionals/physician_gls/default.aspx"
                }
            ],
            "ampCapAscoEvidenceLevel": "A",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 19241,
            "approvalStatus": "Phase I",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase I trial, CC-90011 treatment demonstrated safety, and resulted in a prolonged stable disease of at least 4 months in 7 patients (n=26) with neuroendocrine neoplasm (5 bronchial and 2 prostate) (Annals of Oncology, Volume 30, Issue Supplement_1, Feb 2019, mdz029; NCT02875223).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 8965,
                "therapyName": "CC-90011",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 16841,
                    "pubMedId": null,
                    "title": "Phase I study of CC-90011 in patients with advanced solid tumors and relapsed/refractory non-Hodgkin lymphoma (R/R NHL)",
                    "url": "https://academic.oup.com/annonc/article/30/Supplement_1/mdz029/5364373"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20606,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, treatment with Toripalimab (JS001) resulted in an objective response rate of 20% (8/40), a disease control rate of 35% (14/40), a median duration of response of 15.2 months, a median progression-free survival of 2.5 months, and a median overall survival of 7.8 months in patients with neuroendocrine tumors (PMID: 32086343; NCT03167853).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 5891,
                "therapyName": "Toripalimab",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 17958,
                    "pubMedId": 32086343,
                    "title": "Efficacy, safety and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32086343"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20607,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, treatment with Toripalimab (JS001) resulted in a significantly greater objective response rate (42.9% vs 8.3%, P=0.034) and improved median overall survival (9.1 mo vs 7.2 mo) in patients with neuroendocrine tumors who were positive for CTLA4 (PD-L1 expression greater than or equal to 1%, n=14/38) compared to patients who were negative for CTLA4 (PD-L1 expression less than 1%, n=24/38) (PMID: 32086343; NCT03167853).",
            "molecularProfile": {
                "id": 7639,
                "profileName": "CTLA4 positive"
            },
            "therapy": {
                "id": 5891,
                "therapyName": "Toripalimab",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17958,
                    "pubMedId": 32086343,
                    "title": "Efficacy, safety and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32086343"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20608,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, treatment with Toripalimab (JS001) resulted in a significantly greater objective response rate (50% vs 10.7%, p=0.019) and an improved median progression-free survival (3.8 mo vs 2.2 mo) and median overall survival (9.1 mo vs 7.2 mo) in patients with neuroendocrine tumors with high expression of CTLA4 (PD-L1 greater than or equal to 10%, n=10/38) compared to patients with low expression of CTLA4 (PD-L1 less than 10%, n=28/38) (PMID: 32086343; NCT03167853).",
            "molecularProfile": {
                "id": 31081,
                "profileName": "CTLA4 over exp"
            },
            "therapy": {
                "id": 5891,
                "therapyName": "Toripalimab",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17958,
                    "pubMedId": 32086343,
                    "title": "Efficacy, safety and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32086343"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 20609,
            "approvalStatus": "Phase Ib/II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase Ib trial, patients with a neuroendocrine tumor with high tumor mutational burden (TMB high, greater than 9.9 muts/Mb, n=4) compared to patients with a TMB less than 9.9 muts/Mb (n=34) demonstrated a greater objective response rate (75% vs 16.1%) and disease control rate (100% vs 29%) when treated with Toripalimab (JS001) (PMID: 32086343; NCT03167853).",
            "molecularProfile": {
                "id": 29716,
                "profileName": "TMB high"
            },
            "therapy": {
                "id": 5891,
                "therapyName": "Toripalimab",
                "synonyms": null
            },
            "indication": {
                "id": 169,
                "name": "neuroendocrine tumor",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 17958,
                    "pubMedId": 32086343,
                    "title": "Efficacy, safety and biomarkers of toripalimab in patients with recurrent or metastatic neuroendocrine neoplasms: a multiple-center phase Ib trial.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/32086343"
                }
            ],
            "ampCapAscoEvidenceLevel": "C",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00926640",
            "title": "A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1123,
                    "therapyName": "Belinostat + Cisplatin + Etoposide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01177397",
            "title": "Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma",
            "phase": "Phase Ib/II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 693,
                    "therapyName": "CC-223",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01466036",
            "title": "Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 998,
                    "therapyName": "Cabozantinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01841736",
            "title": "Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 848,
                    "therapyName": "Pazopanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02063958",
            "title": "Safety and Pharmacology of SNX-5422 Plus Everolimus in Subjects With Neuroendocrine Tumors",
            "phase": "Phase I",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 866,
                    "therapyName": "SNX-5422",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02205515",
            "title": "An Open Label, Single-Centre, Phase II Study of Everolimus With EBRT for the Treatment of mNET Liver Metastasis",
            "phase": "Phase Ib/II",
            "recruitment": "Unknown status",
            "therapies": [
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02250885",
            "title": "KPT-330 to Treat Poorly Differentiated Lung and Gastroenteropancreatic Tumors",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 1749,
                    "therapyName": "Selinexor",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02259725",
            "title": "Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 890,
                    "therapyName": "Regorafenib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02279433",
            "title": "A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4343,
                    "therapyName": "DS6051b",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02315625",
            "title": "Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 735,
                    "therapyName": "Everolimus",
                    "synonyms": null
                },
                {
                    "id": 930,
                    "therapyName": "Sunitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02399215",
            "title": "Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 831,
                    "therapyName": "Nintedanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02402920",
            "title": "Phase I Trial of MK-3475 and Concurrent Chemo/Radiation for the Elimination of Small Cell Lung Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2604,
                    "therapyName": "Carboplatin + Etoposide + Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02420691",
            "title": "LEE011 in Neuroendocrine Tumors of Foregut Origin",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 790,
                    "therapyName": "Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02454972",
            "title": "Clinical Trial of Lurbinectedin (PM01183) in Selected Advanced Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1195,
                    "therapyName": "Lurbinectedin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02487095",
            "title": "Trial of Topotecan With VX-970, an ATR Kinase Inhibitor, in Small Cell Lung Cancer",
            "phase": "Phase Ib/II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2879,
                    "therapyName": "VX-970",
                    "synonyms": null
                },
                {
                    "id": 942,
                    "therapyName": "Topotecan",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02489903",
            "title": "RRx-001 in Small, Non-small Cell Lung Cancer, and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1136,
                    "therapyName": "Etoposide",
                    "synonyms": null
                },
                {
                    "id": 3680,
                    "therapyName": "RRx-001",
                    "synonyms": null
                },
                {
                    "id": 1092,
                    "therapyName": "Carboplatin",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 619,
                    "therapyName": "Nab-paclitaxel",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02628067",
            "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02631733",
            "title": "Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",
            "phase": "Phase I",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 3314,
                    "therapyName": "Irinotecan + Veliparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02754297",
            "title": "Personalized PRRT of Neuroendocrine Tumors (P-PRRT)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6696,
                    "therapyName": "lutetium Lu 177 dotatate",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02795858",
            "title": "A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 4266,
                    "therapyName": "Octreotide + Ramucirumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02831179",
            "title": "Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor",
            "phase": "Phase I",
            "recruitment": "Withdrawn",
            "therapies": [
                {
                    "id": 4463,
                    "therapyName": "Capecitabine + Temozolomide + Veliparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02936323",
            "title": "PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers",
            "phase": null,
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 5819,
                    "therapyName": "PEN-221",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02939651",
            "title": "A Study of Pembrolizumab in Patients With Neuroendocrine Tumors",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02955069",
            "title": "Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2659,
                    "therapyName": "Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03014297",
            "title": "Fosbretabulin With Everolimus in Neuroendocrine Tumors With Progression",
            "phase": "Phase I",
            "recruitment": "Terminated",
            "therapies": [
                {
                    "id": 5207,
                    "therapyName": "Everolimus + Fosbretabulin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03034200",
            "title": "Phase 2 Study of ONC201 in Neuroendocrine Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1687,
                    "therapyName": "ONC201",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03070301",
            "title": "A Study of LEE011 With Everolimus in Patients With Advanced Neuroendocrine Tumors",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 5073,
                    "therapyName": "Everolimus + Ribociclib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03074513",
            "title": "Atezolizumab and Bevacizumab in Rare Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4595,
                    "therapyName": "Atezolizumab + Bevacizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03211988",
            "title": "Entinostat Neuroendocrine (NE) Tumor",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1541,
                    "therapyName": "Entinostat",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03289741",
            "title": "A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide",
            "phase": "FDA approved",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6279,
                    "therapyName": "Lanreotide Depot + Octreotide",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03290079",
            "title": "Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas",
            "phase": "Phase II",
            "recruitment": "Suspended",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03365791",
            "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies",
            "phase": "Phase II",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2887,
                    "therapyName": "LAG525",
                    "synonyms": null
                },
                {
                    "id": 2659,
                    "therapyName": "Spartalizumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03375320",
            "title": "Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery",
            "phase": "Phase III",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 998,
                    "therapyName": "Cabozantinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03411915",
            "title": "A Study of XmAb18087 in Subjects With NET and GIST",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 7309,
                    "therapyName": "XmAb18087",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03420521",
            "title": "Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1627,
                    "therapyName": "Ipilimumab + Nivolumab",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03457948",
            "title": "Pembrolizumab and Liver-Directed Therapy in Treating Patients With Well-Differentiated Neuroendocrine Tumors and Symptomatic and/or Progressive Liver Metastases",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1447,
                    "therapyName": "Pembrolizumab",
                    "synonyms": null
                },
                {
                    "id": 6762,
                    "therapyName": "Pembrolizumab + Yttrium-90",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03517488",
            "title": "A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2)",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 6973,
                    "therapyName": "XmAb20717",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03950609",
            "title": "Lenvatinib and Everolimus in Treating Patients With Advanced, Unresectable Carcinoid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1713,
                    "therapyName": "Everolimus + Lenvatinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT04197310",
            "title": "Cabozantinib and Nivolumab for Carcinoid Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2067,
                    "therapyName": "Cabozantinib + Nivolumab",
                    "synonyms": null
                }
            ]
        }
    ]
}